Gambini Juan P, Nuñez Margarita, Cabral Pablo, Lafferranderie Martín, Noble Javier, Corchs Eduardo, D'Albora Ricardo, Savio Eduardo, Delgado Lucía, Alonso Omar
Nuclear Medicine Center, Clinical Hospital, University of Uruguay, Montevideo, Uruguay.
J Nucl Med Technol. 2009 Dec;37(4):229-32. doi: 10.2967/jnmt.109.062927.
Preliminary findings have suggested that (99m)Tc-glucarate has tumor-seeking properties. The purpose of this study was to explore the potential of this tracer to evaluate malignant head and neck tumors by means of SPECT/CT software fusion imaging.
Eleven male patients with advanced head and neck carcinoma were included in the study: 9 with locally advanced disease and 2 with clinical suspicion of local relapse. Scanning started 3-6 h after the injection of 1,110 MBq of (99m)Tc-glucarate. Planar and SPECT images of the head, neck, and thorax were acquired. Three-dimensional images were also coregistered with CT.
We found (99m)Tc-glucarate uptake in all suspected lesions. SPECT/CT fusion imaging was helpful in all cases for topographically localizing the tracer foci.
(99m)Tc-glucarate can be considered a potential tracer for the evaluation of patients with head and neck tumors.